A busy June at the FDA includes 11 upcoming PDUFA dates, with at least eight new products and three label expansions awaiting decisions, according to a regulatory calendar overview. One of the highest-profile items at the month’s end is a potential label expansion for Ionis Pharmaceuticals’ Tryngolza (olezarsen). Tryngolza is currently approved for familial chylomicronemia syndrome (FCS), with the decision focused on whether the antisense oligonucleotide will expand into severe hypertriglyceridemia—an effort that would scale the addressable market beyond the ultrarare indication. If approved for the broader condition, it would represent Ionis’ first wholly owned product to move into a much larger patient population. For biotech investors and platform stakeholders, these PDUFA timelines remain a key near-term catalyst for pipeline valuation and payer discussions, particularly where label scope expansion can materially shift commercial adoption.